Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.73M | 10.00M | 10.00M | 439.00K | 9.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.73M | 10.00M | 10.00M | 439.00K | 9.34M |
| Cost of Revenue | 122.17M | 120.41M | 109.67M | 93.65M | 77.05M |
| Gross Profit | -108.43M | -110.41M | -99.67M | -93.21M | -67.71M |
| SG&A Expenses | 43.06M | 41.77M | 39.13M | 46.18M | 43.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 170.72M | 167.67M | 154.29M | 145.32M | 122.92M |
| Operating Income | -156.98M | -157.67M | -144.29M | -144.88M | -113.58M |
| Income Before Tax | -114.48M | -113.63M | -101.90M | -105.64M | -77.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -114.48 | -113.63 | -101.90 | -105.64 | -77.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.48M | -113.63M | -101.90M | -105.64M | -77.74M |
| EBIT | -156.98M | -157.67M | -144.29M | -144.88M | -113.58M |
| EBITDA | -155.00M | -155.64M | -142.22M | -142.80M | -111.54M |
| EPS Basic | -1.84 | -1.83 | -1.68 | -1.80 | -1.36 |
| Normalized Basic EPS | -1.15 | -1.15 | -1.05 | -1.12 | -0.85 |
| EPS Diluted | -1.84 | -1.83 | -1.68 | -1.80 | -1.36 |
| Normalized Diluted EPS | -1.15 | -1.15 | -1.05 | -1.12 | -0.85 |
| Average Basic Shares Outstanding | 248.74M | 247.86M | 242.55M | 235.16M | 227.70M |
| Average Diluted Shares Outstanding | 248.74M | 247.86M | 242.55M | 235.16M | 227.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |